1. Gut membrane proteins as candidate antigens for immunization of mice against the tick Amblyomma sculptum.
- Author
-
Costa GCA, Ribeiro ICT, Giunchetti RC, Gontijo NF, Sant'Anna MRV, Pereira MH, Pessoa GCD, Koerich LB, Oliveira F, Valenzuela JG, Fujiwara RT, Bartholomeu DC, and Araujo RN
- Subjects
- Animals, Mice, Female, Immunization methods, Membrane Proteins immunology, Membrane Proteins genetics, Immunoglobulin G blood, Immunoglobulin G immunology, Recombinant Proteins immunology, Recombinant Proteins genetics, Tick Infestations prevention & control, Tick Infestations immunology, Rickettsia rickettsii immunology, Brazil, Male, Mice, Inbred BALB C, Antigens immunology, Amblyomma immunology
- Abstract
Amblyomma sculptum is widely distributed in Brazil and is the main vector of Rickettsia rickettsii, the causative agent of the Brazilian spotted fever (BSF). Tick gut proteins play an essential role in blood feeding, digestion, and protection of gut epithelium. Therefore, many of these were investigated as potential vaccine targets for tick-control strategies. The present study aimed to select transcripts corresponding to putative immunogenic proteins in the A. sculptum gut epithelial membrane, produce recombinant proteins and evaluate them as antigens against A. sculptum infestations. Three gut proteins - AsMucin, AsAPP, and AsLAMP - and a chimeric protein (rAsChimera) based on 22 peptides containing putative B cell epitopes from seven different gut proteins were evaluated as anti-A. sculptum antigens. Mice immunizations revealed that all recombinant targets elicited humoral response with significantly increased IgG levels compared to controls. For rAsChimera, IgG levels remained significantly higher than controls up to 75 days after the end of the immunization. Challenge trials revealed that vaccination with the chimeric protein was the most effective against A. sculptum, inducing 100 % nymph mortality and reaching 80.8 % efficacy against females. The other three proteins did not induce relevant protection, as AsAPP had only 26.6 % efficacy, whereas AsMucin and AsLAMP induced no protection. These data indicate that targeting gut protein immunogenic regions may be an effective strategy for a vaccine formulation againstA. sculptum., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ricardo Nascimento Araujo has patent #BR 10 2019 018609 7 pending to INPI- Instituto Nacional de Propriedade Intelectual. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF